Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.

@article{Montesinos2003AdenosineAO,
  title={Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68.},
  author={Mar{\'i}a Carmen Montesinos and Avani Desai and Dave Delano and Jiang-fan Chen and J. Stephen Fink and Marlene A. Jacobson and Bruce Cronstein},
  journal={Arthritis and rheumatism},
  year={2003},
  volume={48 1},
  pages={240-7}
}
OBJECTIVE Low-dose weekly methotrexate therapy remains a mainstay in the treatment of inflammatory arthritis. Results of previous studies demonstrated that adenosine, acting at one or more of its receptors, mediates the antiinflammatory effects of methotrexate in animal models of both acute and chronic inflammation. We therefore sought to establish which receptor(s) is involved in the modulation of acute inflammation by methotrexate and its nonpolyglutamated analog MX-68 (N-[[4-[(2,4… CONTINUE READING